

产品名称: **Cabotegravir**
 产品别名: **UNII-HMH0132Z1Q; 卡博特韦**

生物活性:																										
Description	Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μ M) and OAT3 (IC50 0.41 μ M). IC50 value: 0.81 μ M (OAT1), 0.41 μ M (OAT3) [1] Target: OAT1, OAT3 Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]																									
	In Vitro: DMSO : 12.67 mg/mL (31.26 mM; Need ultrasonic and warming) <table> <tr> <th rowspan="2"></th><th rowspan="2">Solvent Concentration</th><th colspan="3">Mass</th></tr> <tr> <th>1 mg</th><th>5 mg</th><th>10 mg</th></tr> <tr> <td>Preparing</td><td>1 mM</td><td>2.4670 mL</td><td>12.3350 mL</td><td>24.6700 mL</td></tr> <tr> <td>Stock Solutions</td><td>5 mM</td><td>0.4934 mL</td><td>2.4670 mL</td><td>4.9340 mL</td></tr> <tr> <td></td><td>10 mM</td><td>0.2467 mL</td><td>1.2335 mL</td><td>2.4670 mL</td></tr> </table>					Solvent Concentration	Mass			1 mg	5 mg	10 mg	Preparing	1 mM	2.4670 mL	12.3350 mL	24.6700 mL	Stock Solutions	5 mM	0.4934 mL	2.4670 mL	4.9340 mL		10 mM	0.2467 mL	1.2335 mL
	Solvent Concentration	Mass																								
		1 mg	5 mg	10 mg																						
Preparing	1 mM	2.4670 mL	12.3350 mL	24.6700 mL																						
Stock Solutions	5 mM	0.4934 mL	2.4670 mL	4.9340 mL																						
	10 mM	0.2467 mL	1.2335 mL	2.4670 mL																						
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。																										
References	[1]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.																									
	[2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [3]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16.																									

源叶生物